A high TMB in one GBM patient with mutations in the gene coding DNA polymerase epsilon (POLE) led to a systemic response to pembrolizumab (PD1 inhibitor), thus supporting this hypothesis [76]. The gene discussed is PDCD1; the disease is glioblastoma.